香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 內幕消息 主要股東變動 本公告由中國儲能科技發展有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09 (2) (a)條及證券 及期貨條例（ 香港法例第571章 ）第XIVA部之內幕消息條文（ 定義見上市規則 ）而作 出。 本公司主要股東陳德柱先生（「賣方」）於二零二五年十二月十二日（ 交易時段後 ）通 知 本 公 司 ， 其 已 向 於 英 屬 處 女 群 島 註 冊 成 立 之 有 限 公 司 Fame Castle Enterprises Limited（「買方」）出售合共51,760,000股本公司股份（「股份」），相當於本公告日期已 發行股份約23.1 %（「該轉讓」） ...

日前，中国储能科技发展发布公告，有关拟收购Circuit Development Limited的全部已发行股本，买卖协 议的所有先决条件已获达成，且收购事项已于2025年9月18日根据买卖协议的条款及条件完成。 香港联交所最新资料显示，12月2日，中国储能科技发展(01143)股东将股票存入结好证券，存仓市值 2226万港元，占比23.63%。 ...

日前，中国储能科技发展发布公告，有关拟收购Circuit Development Limited的全部已发行股本，买卖协 议的所有先决条件已获达成，且收购事项已于2025年9月18日根据买卖协议的条款及条件完成。 智通财经APP获悉，香港联交所最新资料显示，12月2日，中国储能科技发展(01143)股东将股票存入结 好证券，存仓市值2226万港元，占比23.63%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國儲能科技發展有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01143 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,500,000,000 | HKD | | 0.2 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 7,500,000,000 | HKD | | 0.2 | HKD | | 1,500,000,000 | 本月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國儲能科技發展有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01143 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 224,289,185 | | | | 224,289,185 | | 增加 / 減少 (-) | | | 0 | | | | | | 本月底結存 | | | 224,289,185 | | 0 | | 224,289,185 | | 1. 股份分類 | 普 ...

公司名稱: 中國儲能科技發展有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01143 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,500,000,000 | HKD | | 0.2 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 7,500,000,000 | HKD | | 0.2 | HKD | | 1,500,000,000 | 本月底法定/註冊股本總額： HKD 1,500,000,000 F ...

(Stock code: 1143) （Stock Code 股份代號：1143） NOTIFICATION LETTER 通知信函 (formerly known as Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） 30 September 2025 Dear Non-registered Holder(s) (Note 1) , China Energy Storage Technology Development Limited (the "Company") — Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English an ...

(formerly known as Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code: 1143) （Stock Code 股份代號：1143） NOTIFICATION LETTER 通知信函 30 September 2025 It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends ...

Revenue Performance - Revenue from continuing operations decreased from approximately HK$264.7 million for the six months ended June 30, 2024, to approximately HK$188.2 million for the six months ended June 30, 2025, representing a decline of about 29%[5]. - Revenue from the EMS segment decreased by approximately HK$63.4 million, primarily due to reduced business in the European and US markets[6]. - The revenue from the EMS business decreased by 25.6% to HK$184.0 million for the six months ended June 30, 2025, compared to HK$247.4 million in 2024[9]. - The Real Estate Supply Chain Services business revenue decreased by 11.2% to HK$4.3 million for the six months ended June 30, 2025, from HK$4.8 million in 2024[15]. - The Securities and Other Assets Investment segment generated approximately HK$nil in revenue for the six months ended June 30, 2025, down from HK$12.2 million in 2024[16]. - Total revenue for the period ended 30 June 2025 was HK$188.2 million, a decrease of 28.9% compared to HK$264.7 million in 2024[55][61]. - Revenue contributions from major European countries totaled HK$65.7 million, accounting for 34.9% of total turnover for the six months ended June 30, 2025[52]. - The United States market contributed HK$39.9 million in revenue, representing 21.2% of total turnover for the same period[52]. - The People's Republic of China and other countries accounted for HK$26.1 million and HK$56.5 million in revenue, respectively, for the six months ended June 30, 2025[52]. - Revenue from external customers for the six months ended June 30, 2025, was HK$188,226,000, a decrease from HK$264,698,000 in the same period of 2024, representing a decline of approximately 29%[192][194]. Financial Position - As of June 30, 2025, the Group had bank and cash balances totaling approximately HK$331.3 million, an increase from HK$312.1 million as of December 31, 2024[8]. - The Group's current ratio was 2.6 times, with cash and cash equivalents amounting to HK$331.3 million, an increase of HK$19.3 million from the previous period[81][86]. - Total assets as of June 30, 2025, were HK$875,181,000, slightly down from HK$880,137,000 at the end of 2024[181]. - Total current assets remained stable at HK$801,876,000 compared to HK$801,491,000 at the end of 2024[181]. - Non-current assets decreased to HK$73,305,000 from HK$78,646,000, reflecting a decline in property, plant, and equipment[181]. - Total liabilities as of June 30, 2025, amounted to HK$343,001,000, a slight decrease of 0.1% from HK$343,252,000 as of December 31, 2024[182]. - Current liabilities increased to HK$305,614,000 from HK$301,130,000, reflecting a rise of 1.6%[182]. - Total liabilities amounted to 343,001 million, slightly down from 343,252 million year-over-year[199]. - Borrowing increased to 17,300 million from 14,300 million, reflecting a growth of approximately 21%[199]. - Bonds payable rose to 33,827 million, up from 25,041 million, indicating a significant increase of about 35%[199]. - Total equity attributable to owners of the company as of June 30, 2025, was HK$532,180,000, reflecting a decrease from HK$536,531,000 as of December 31, 2024[184]. Profitability and Losses - Gross profit fell 44.4% to HK$41.0 million, with a gross profit margin of 21.8%, down from 27.8% in 2024[57][63]. - The loss attributable to owners of the Company was HK$16.3 million, with a net loss margin of 8.6%[73][79]. - Loss for the period was HK$16,497,000, compared to a loss of HK$4,786,000 in the prior year, indicating a significant increase in losses[180]. - Basic loss per share increased to 7.26 HK cents from 1.96 HK cents in the previous year[179]. - The company reported a total comprehensive loss of HK$10,011,000 for the period, compared to a loss of HK$10,154,000 in the previous year[180]. - The company reported a consolidated loss before tax of HK$15,725,000 for the six months ended June 30, 2025, compared to a loss of HK$1,521,000 in the same period of 2024[194]. Credit and Risk Management - The Group has established strict credit policies and controls to mitigate credit risks, including thorough credit assessments and due diligence during the loan application process[26][28]. - The Group's impairment losses primarily relate to the expected credit loss (ECL) allowance for loans and interest receivables, assessed based on historical credit loss experience and current economic conditions[31][34]. - The management continuously monitors the credit quality of each borrower to minimize exposure to credit risk[50]. - The Group performs public searches on borrowers and guarantors to ensure compliance with anti-money laundering and counter-terrorist financing regulations[36][37]. - Legal actions for loan recovery will be considered on a case-by-case basis to minimize potential credit losses[26][28]. - The Group's expected credit loss (ECL) assessments are based on historical credit loss experience and adjusted for specific debtor factors and economic conditions[47]. - For the six months ended June 30, 2025, the Group recorded an impairment loss on loans and interest receivable of approximately HK$nil, indicating effective credit risk management[47]. Business Strategy and Operations - The Group plans to close down the subsidiary in the Distribution Segment due to the continuing decrease in demand for business telephone system products in North America[11]. - The Group has commenced the energy storage business in 2023, aligning with government policies to achieve carbon neutrality goals[7]. - The Group is closely monitoring global economic challenges, including high interest rates and geopolitical conflicts, to adjust its business development strategy accordingly[108]. - The company continues to focus on its core operations while exploring opportunities for market expansion and new product development[192]. - The energy storage industry in China is expected to experience rapid growth driven by government policies and market demand, particularly in lithium battery energy storage[105][106]. - The Chinese energy storage industry is experiencing rapid growth driven by government policies and market demand, with a focus on lithium battery storage in the short term and multi-technology integration in the medium to long term[109]. - The company plans to invest approximately $5,000,000 in a subsidiary registered in Cambodia within the next 12 months, including the establishment of production facilities[109]. - The company is enhancing its marketing efforts to attract potential customers in the United States, benefiting from tax incentives for exports[109]. Share Options and Equity - As of June 30, 2025, there were 2,621,296 share options valid and outstanding under the 2020 Share Option Scheme[138]. - On November 3, 2023, 15,695,082 share options were granted to employees and directors under the 2023 Share Option Scheme[140]. - The total number of shares available for issue under the Share Option Scheme was 18,171,478, representing approximately 8.1% of the issued shares as of the report date[142]. - The 2023 Share Option Scheme and 2023 Share Award Plan were adopted at the 2023 AGM, terminating the 2020 Share Option Scheme[139]. - The maximum entitlement for each participant under the 2023 Share Award Plan is capped at 1% of the issued share capital of the Company within any 12-month period[153]. - The share options granted are intended to recognize past contributions and encourage future performance, with specific terms under which they may lapse[159]. - The share option scheme aims to align the interests of grantees with those of the Company and its shareholders[151]. - The Company did not grant any share options to directors or senior managers during the six months ended June 30, 2025, as per the Listing Rules[164].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 建議更新計劃授權限額 建議更新計劃授權限額 根據二零二三年購股權計劃，二零二三年購股權計劃項下可授出購股權涉及的最 高 股 份 數 目 不 得 超 過 於 二 零 二 三 年 六 月 八 日 採 納 日 期 已 發 行 股 份 總 數 的 10 %（ 即 合共17,252,918股股份 ）。 於二零二三年購股權計劃期間及直至本公告日期，本公司已於二零二三年十一月 三 日授 出合 共15,695,082 份購 股權 。二 零 二三 年購 股權 計 劃項 下144,900 份 購股 權 已失效，並無購股權已獲行使，二零二三年購股權計劃項下15,550,182份購股權尚 未行使。 於本公告日期，本公司並無具體計劃或意向，以於本公告日期後及直至股東特別 ...